American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 148; no. 1; pp. 221 - 244.e3
• Main Authors: Perrillo, Robert P, Gish, Robert, Falck-Ytter, Yngve T
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2015
• Subjects: Antiviral Agents - therapeutic use; Biomarkers - blood; DNA, Viral - blood; Gastroenterology; Gastroenterology and Hepatology; Hepatitis B - diagnosis; Hepatitis B - drug therapy; Hepatitis B - immunology; Hepatitis B - prevention & control; Hepatitis B - virology; Hepatitis B Antibodies - blood; Hepatitis B Surface Antigens - blood; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B virus - immunology; Hepatitis B virus - pathogenicity; Humans; Immunosuppressive Agents - adverse effects; Recurrence; Risk Factors; Societies, Medical; Treatment Outcome; Viral Load; Virus Activation - drug effects; anti-HBs; PICO; RR; rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; FDA; RCT; hepatitis B virus reactivation; antibody to hepatitis B core antigen; hepatitis B virus; alanine aminotransferase; ALT; antibody to hepatitis B surface antigen; population, intervention, comparison, and outcome; TNF; hepatitis B e antigen; CHOP; transarterial chemoembolization; HBV; Food and Drug Administration; AST; hepatitis B surface antigen; CI; R-CHOP; HBeAg; TACE; HBsAg; relative risk; aspartate aminotransferase; randomized controlled trial; anti-HBc; Grading of Recommendations Assessment, Development and Evaluation; tumor necrosis factor; HBVr; GRADE; cyclophosphamide, doxorubicin, vincristine, and prednisone; confidence interval
• ISSN: 0016-5085; 1528-0012
• DOI: 10.1053/j.gastro.2014.10.038